ARCHIVES

As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Freeman Reappointed President’s Cancer Panel Chairman

September 16, 1994

Spending Measures Include Provisions On Ethics For NIH Extramural Scientists.

July 11, 2008

Ratain To Lead New Center For Personalized Therapeutics At University of Chicago. Report Calls For Better Risk Stratification And New Name For DCIS.

January 22, 2010

Also in this 8-page issue: NCI contract will keep Cancer Genetics Network database alive, but center grants will not be recompeted.

July 23, 2004

In Brief: Moorehead Heads ACCC; Anderson President Elect; Segaloff Dies; RAAD Cleveland Clinic Director

March 22, 1985

NCI advisors table proposed $186.5 million nanotechnology research program. NCI proposed to fund three to five “centers for cancer nanotechnology excellence,” a coordinating center, and training programs. Board members said they needed more time, information, to make decision. NCI director asked board to “think big” about nanotechnology. Deputy director called nanotechnology program “transformational.”

July 2, 2004